EPR: 2022 biopharma trend predictions roundtable

Scroll Down

From supply challenges surrounding COVID-19 to regulatory changes and innovations, the year 2022 is set to be an interesting year for biopharma manufacturing companies around the world.

Here, Bill Vincent, Founder and Executive Chairman at Genezen provides his insights into the top biopharma trends we can expect to see in 2022. He also highlights the impact of regulatory changes on serum use for cell growth and the potential of stable producer cell lines throughout cell and gene therapy manufacturing.

Read the full article: Key challenges for biopharmaceutical manufacturing 2022

You may also be interested in...

Genezen completes cGMP-lentiviral and retroviral vector…

Genezen, a cell and gene therapy Contract Development and Manufacturing Organization...

Read more

Genezen announces launch of Scientific Advisory…

Leading experts in cell and gene therapy will provide guidance to...

Read more

Overcoming development and manufacturing challenges with…

As efficient and effective tools for gene transduction and delivering genes...

Read more

Retroviruses in CAR-T therapies: From gamma…

Introduction In recent years, chimeric antigen receptor T (CAR-T) cells have...

Read more